This will enable to locate patients at risk of developing sporadic colorectal cancer and perhaps find pre-cancerous polyps ahead of time. This could also affect the time when an individual begins initial testing instead of the normal standards. More genomics research in the works. BD
Orion Genomics, which develops cancer screening tests, entered into a worldwide exclusive licensing agreement with Johns Hopkins University to commercialize Orion's lead cancer risk assessment product enabling the company to enter the market in the near future, the company announced Wednesday.